Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Net Cash Flow (2017 - 2025)

Dianthus Therapeutics has reported Net Cash Flow over the past 8 years, most recently at $42.7 million for Q3 2025.

  • Quarterly results put Net Cash Flow at $42.7 million for Q3 2025, up 115.23% from a year ago — trailing twelve months through Sep 2025 was $22.3 million (up 118.02% YoY), and the annual figure for FY2024 was -$109.4 million, down 193.5%.
  • Net Cash Flow for Q3 2025 was $42.7 million at Dianthus Therapeutics, up from $3.1 million in the prior quarter.
  • Over the last five years, Net Cash Flow for DNTH hit a ceiling of $197.4 million in Q1 2024 and a floor of -$280.3 million in Q3 2024.
  • Median Net Cash Flow over the past 4 years was -$10.9 million (2024), compared with a mean of $3.2 million.
  • Peak annual rise in Net Cash Flow hit 2415.6% in 2024, while the deepest fall reached 339.72% in 2024.
  • Dianthus Therapeutics' Net Cash Flow stood at -$21.5 million in 2022, then dropped by 15.99% to -$25.0 million in 2023, then soared by 56.41% to -$10.9 million in 2024, then soared by 492.38% to $42.7 million in 2025.
  • The last three reported values for Net Cash Flow were $42.7 million (Q3 2025), $3.1 million (Q2 2025), and -$12.7 million (Q1 2025) per Business Quant data.